[1] |
GLOBOCAN 2008 (IARC) Section of Cancer Information (18/4/2011).
|
[2] |
Saltz L, Clarke S, Diaz-Rubio E,et al.Bevacizumab in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1 /NO16966,a randomized phase Ⅲ trial in first-line metastatic colorectal cancer[J].J Clin Oncol,2007,25(7):1346-1355.
|
[3] |
王占魁,翟栋材.门静脉高压症的影像学诊断[J].临床荟萃,2002,17(23):1426-1426.
|
[4] |
陈坤,黄秋驰.结直肠癌人群筛查研究进展[J].中国癌症防治杂志,2017,9(2):94-99.
|
[5] |
朱德祥,许剑民.2017年中国临床肿瘤学会年会结直肠癌研究进展解析[J].中华消化外科杂志,2017,16(11):1101-1104.
|
[6] |
陈喆,贾贝,乔涌起,等.结直肠癌患者化疗后肝功能异常的分析[J].临床药物治疗杂志,2015,13(1):53-57.
|
[7] |
Khan Aamir Z, Morris-Stiff Gareth, Makuuchi Masatoshi.Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases[J].J Hepatobiliary Pancreat Surg,2009,16(2):137-144.
|
[8] |
Mehta NN, Ravikumar R, Coldham CA,et al.Effect of preoperative chemotherapy on liver resection for colorectal liver metastases[J].Eur J Surg Oncol,2008,34(7):782-786.
|
[9] |
Kneuertz PJ, Maithel SK, Staley CA,et al. Chemotherapy-associated liver injury:impact on surgical management of colorectal cancer liver metastases[J].Ann Surg Oncol,2011,18(1):181-190.
|
[10] |
Rubbia-Brandt L, Mentha G, Terris B.Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases[J].J.Am Coll Surg,2006,202(1):199-200.
|
[11] |
Gu HK, Moon H S, Lee ES,et al.A case of liver fibrosis with splenomegaly after oxaliplatin-based adjuvant chemotherapy for colon cancer[J].J Korean Med Sci,2013,28(12):1835-1838.
|
[12] |
Heo Jun, Shin Keun Young, Kwon Yong Hwan,et al.[A case of portal hypertension after the treatment of oxaliplatin based adjuvant chemotherapy for rectal cancer][J].Korean J Gastroenterol,2011,57(4):253-257.
|
[13] |
Ogata Hiroaki, Gushima Toshifumi, Maruoka Shinko, et al.[A case of portal hypertension after 5-fluorouracil,leucovorin,and oxaliplatin (mFOLFOX6) chemotherapy][J].Nihon Shokakibyo Gakkai Zasshi,2013,110(12):2119-226.
|
[14] |
Slade JH, Alattar ML, Fogelman DR, et al.Portal hypertension associated with oxaliplatin administration:clinical manifestations of hepatic sinusoidal injury[J].Clin Colorectal Cancer,2009,8(4):225-230.
|
[15] |
Overman Michael J, Maru Dipen M, Charnsangavej Chusilp,et al.Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury[J].J Clin Oncol,2010,28(15):2549-2555.
|
[16] |
张正华,侯凯生,谢芳,等.XPD和ERCC1基因多态性与进展期结直肠癌患者铂剂为基础化疗方案治疗的毒副作用[J].现代生物医学进展,2015,15(6):1046-1049.
|